• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

唐氏综合征筛查中风险评估的改进参数。

Improved parameters for risk estimation in Down's syndrome screening.

作者信息

Cuckle H

机构信息

Institute of Epidemiology and Health Services Research, Research School of Medicine, Leeds, U.K.

出版信息

Prenat Diagn. 1995 Nov;15(11):1057-65. doi: 10.1002/pd.1970151111.

DOI:10.1002/pd.1970151111
PMID:8606885
Abstract

A new method is described for calculating maternal serum marker distribution parameters which will improve risk estimation when screening for Down's syndrome. The approach is to calculate parameters using data from the local screened population and data obtained by meta-analysis from all published studies. The local data are used to derive the variance and covariance in unaffected pregnancies. The meta-analysis is used for the mean level in Down's syndrome pregnancies together with the differences in variance and covariance between affected and unaffected pregnancies. Forty-four published studies were analysed. The mean level for Down's syndrome in multiples of the normal median was 0.73 for alpha-fetoprotein (AFP) in total of 1140 pregnancies, 0.73 for unconjugated oestriol (uE3) in 613, 2.02 for human chorionic gonadotropin (hCG) in 850, and 2.30 for free beta-hCG in 477. For all four markers, the variance in Down's syndrome was higher than in unaffected pregnancies; for AFP and uE3, the covariances were also higher in Down's syndrome, but for the other markers they were lower. The method was illustrated using data from 6387 pregnancies screened in Leeds.

摘要

本文描述了一种计算母体血清标志物分布参数的新方法,该方法在唐氏综合征筛查时可改善风险评估。具体做法是利用当地筛查人群的数据以及通过对所有已发表研究进行荟萃分析得到的数据来计算参数。利用当地数据得出未受影响妊娠的方差和协方差。荟萃分析用于获取唐氏综合征妊娠的平均水平以及受影响和未受影响妊娠之间方差和协方差的差异。对44项已发表研究进行了分析。在总共1140例妊娠中,甲胎蛋白(AFP)在唐氏综合征中的平均水平为正常中位数的0.73倍;在613例妊娠中,未结合雌三醇(uE3)为0.73倍;在850例妊娠中,人绒毛膜促性腺激素(hCG)为2.02倍;在477例妊娠中,游离β-hCG为2.30倍。对于所有这四种标志物,唐氏综合征中的方差均高于未受影响的妊娠;对于AFP和uE3,唐氏综合征中的协方差也更高,但对于其他标志物则更低。利用利兹筛查的6387例妊娠数据对该方法进行了说明。

相似文献

1
Improved parameters for risk estimation in Down's syndrome screening.唐氏综合征筛查中风险评估的改进参数。
Prenat Diagn. 1995 Nov;15(11):1057-65. doi: 10.1002/pd.1970151111.
2
First trimester serum tests for Down's syndrome screening.孕早期唐氏综合征筛查的血清学检测
Cochrane Database Syst Rev. 2015 Nov 30;2015(11):CD011975. doi: 10.1002/14651858.CD011975.
3
Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group.妊娠8至14周时唐氏综合征的血清筛查。国际产前筛查研究小组。
Br J Obstet Gynaecol. 1996 May;103(5):407-12. doi: 10.1111/j.1471-0528.1996.tb09765.x.
4
Second-trimester maternal serum screening for Down's syndrome: free beta-human chorionic gonadotrophin (HCG) and alpha-fetoprotein, with or without unconjugated oestriol, compared with total HCG, alpha-fetoprotein and unconjugated oestriol.孕中期唐氏综合征的母体血清筛查:游离β-人绒毛膜促性腺激素(HCG)和甲胎蛋白,有或没有未结合雌三醇,并与总HCG、甲胎蛋白和未结合雌三醇进行比较。
Hum Reprod. 1998 Jan;13(1):220-3. doi: 10.1093/humrep/13.1.220.
5
Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.跨孕期重复测量唐氏综合征筛查检测:评估。
Health Technol Assess. 2010 Jul;14(33):1-80. doi: 10.3310/hta14330.
6
The use of free beta-hCG in antenatal screening for Down's syndrome.游离β-人绒毛膜促性腺激素在唐氏综合征产前筛查中的应用。
Br J Obstet Gynaecol. 1993 Jun;100(6):550-7. doi: 10.1111/j.1471-0528.1993.tb15307.x.
7
Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.二聚体抑制素A作为孕早期唐氏综合征的标志物。
N Engl J Med. 1996 May 9;334(19):1231-6. doi: 10.1056/NEJM199605093341904.
8
Taking account of vaginal bleeding in screening for Down's syndrome.在唐氏综合征筛查中考虑阴道出血情况。
Br J Obstet Gynaecol. 1994 Nov;101(11):948-53. doi: 10.1111/j.1471-0528.1994.tb13037.x.
9
Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome.在孕中期唐氏综合征血清筛查中,将抑制素A与现有标志物相结合。
Prenat Diagn. 1996 Dec;16(12):1095-100. doi: 10.1002/(SICI)1097-0223(199612)16:12<1095::AID-PD997>3.0.CO;2-9.
10
SURUSS in perspective.透视下的SURUSS
Semin Perinatol. 2005 Aug;29(4):225-35. doi: 10.1053/j.semperi.2005.05.006.

引用本文的文献

1
Triple test screening for Down syndrome: an Egyptian-tailored study.唐氏综合征三联筛查:一项埃及定制研究。
PLoS One. 2014 Oct 20;9(10):e110370. doi: 10.1371/journal.pone.0110370. eCollection 2014.
2
Medians for second-trimester maternal serum markers: geographical differences and variation caused by median multiples-of-median equations.孕中期母体血清标志物中位数:地理差异及中位数倍数中位数方程引起的变异
J Clin Pathol. 2006 Jun;59(6):639-44. doi: 10.1136/jcp.2005.034272.
3
Weight correction of MoM values: which method?中位数倍数(MoM)值的体重校正:采用哪种方法?
J Clin Pathol. 2006 Jul;59(7):753-8. doi: 10.1136/jcp.2005.034280. Epub 2006 Apr 7.
4
Rational Down syndrome screening policy.合理的唐氏综合征筛查政策。
Am J Public Health. 1998 Apr;88(4):558-9. doi: 10.2105/ajph.88.4.558.